Sunitinib Malate in Treating Patients With Kidney Cancer

• Status: Completed
• Trial end date: 2014-12-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

PURPOSE: This clinical trial is studying how well sunitinib malate works in treating patients with kidney cancer.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre Antoine Lacassagne
• Treatments: Sunitinib

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed renal cell carcinoma

• Metastatic disease requiring first-line treatment with sunitinib malate

• No prior therapy for metastatic disease

• No symptomatic or uncontrolled cerebral metastasis

PATIENT CHARACTERISTICS:

• Affiliation to the French Social insurance

• Life expectancy ≥ 3 months

• No heart failure

• No chronic unstable disease

• No long QT interval

• No history of another primary cancer

• No severe, uncontrolled acute infection

• No severe, uncontrolled hypertension

• No psychological disorder

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics